{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:30:11Z","timestamp":1787671811498,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"DOI":"10.7759\/cureus.115158","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:54:34Z","timestamp":1787669674000},"source":"Crossref","is-referenced-by-count":0,"title":["Systematic Review of Neuropsychiatric Side Effects Induced by Mefloquine: Evidence From Case Reports and Clinical Studies"],"prefix":"10.7759","author":[{"given":"Saravana Kumar","family":"Ramasubbu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S K Hasib","family":"Reja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World malaria report 2024. (2024). Accessed. July 31, 2026: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2021.152995","article-title":"Cellular targets of mefloquine","volume":"464","author":"Ghosh DK","year":"2021","unstructured":"Ghosh DK, Kumar A, Ranjan A. Cellular targets of mefloquine. Toxicology. 2021, 464:152995. 10.1016\/j.tox.2021.152995","journal-title":"Toxicology"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.1994.00420200116012","article-title":"Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine","volume":"154","author":"Hennequin C","year":"1994","unstructured":"Hennequin C, Bour\u00e9e P, Bazin N, Bisaro F, Feline A. Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch Intern Med. 1994, 154:2360-2.","journal-title":"Arch Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-016-0045-5","article-title":"Neuropsychiatric adverse reactions to mefloquine: a systematic comparison of prescribing and patient safety guidance in the US, UK, Ireland, Australia, New Zealand, and Canada","volume":"5","author":"Nevin RL","year":"2016","unstructured":"Nevin RL, Byrd AM. Neuropsychiatric adverse reactions to mefloquine: a systematic comparison of prescribing and patient safety guidance in the US, UK, Ireland, Australia, New Zealand, and Canada. Neurol Ther. 2016, 5:69-83. 10.1007\/s40120-016-0045-5","journal-title":"Neurol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006491.pub4","article-title":"Mefloquine for preventing malaria during travel to endemic areas","volume":"10","author":"Tickell-Painter M","year":"2017","unstructured":"Tickell-Painter M, Maayan N, Saunders R, Pace C, Sinclair D. Mefloquine for preventing malaria during travel to endemic areas. Cochrane Database Syst Rev. 2017, 10:CD006491. 10.1002\/14651858.CD006491.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.10658.2","article-title":"Antimalarial drugs and the prevalence of mental and neurological manifestations: a systematic review and meta-analysis","volume":"2","author":"Bitta MA","year":"2017","unstructured":"Bitta MA, Kariuki SM, Mwita C, Gwer S, Mwai L, Newton CR. Antimalarial drugs and the prevalence of mental and neurological manifestations: a systematic review and meta-analysis. Wellcome Open Res. 2017, 2:13. 10.12688\/wellcomeopenres.10658.2","journal-title":"Wellcome Open Res"},{"key":"ref7","unstructured":"Study Quality Assessment Tools. (2021). Accessed. August 1, 2026: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200002000-00018","article-title":"Mefloquine-induced psychosis","volume":"19","author":"Havaldar PV","year":"2000","unstructured":"Havaldar PV, Mogale KD. Mefloquine-induced psychosis. Pediatr Infect Dis J. 2000, 19:166-7. 10.1097\/00006454-200002000-00018","journal-title":"Pediatr Infect Dis J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0883073809332700","article-title":"Childhood mefloquine-induced mania and psychosis: a case report","volume":"24","author":"Thapa R","year":"2009","unstructured":"Thapa R, Biswas B. Childhood mefloquine-induced mania and psychosis: a case report. J Child Neurol. 2009, 24:1008-9. 10.1177\/0883073809332700","journal-title":"J Child Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(89)90474-1","article-title":"Acute psychosis after mefloquine","volume":"29","author":"Stuiver PC","year":"1989","unstructured":"Stuiver PC, Ligthelm RJ, Goud TJ. Acute psychosis after mefloquine. Lancet. 1989, 29:282. 10.1016\/s0140-6736(89)90474-1","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-5-74","article-title":"Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report","volume":"5","author":"Tran TM","year":"2006","unstructured":"Tran TM, Browning J, Dell ML. Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report. Malar J. 2006, 5:74. 10.1186\/1475-2875-5-74","journal-title":"Malar J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-34114","article-title":"Mefloquine-induced paranoid psychosis and subsequent major depression in a 25-year-old student","volume":"35","author":"Dietz A","year":"2002","unstructured":"Dietz A, Fr\u00f6lich L. Mefloquine-induced paranoid psychosis and subsequent major depression in a 25-year-old student. Pharmacopsychiatry. 2002, 35:200-2. 10.1055\/s-2002-34114","journal-title":"Pharmacopsychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(89)93029-8","article-title":"Acute psychosis following mefloquine prophylaxis","volume":"7","author":"Bj\u00f6rkman A","year":"1989","unstructured":"Bj\u00f6rkman A. Acute psychosis following mefloquine prophylaxis. Lancet. 1989, 7:865. 10.1016\/s0140-6736(89)93029-8","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2011.01.013","article-title":"Mood disorder after malaria prophylaxis with mefloquine (two case reports)","volume":"37","author":"Oueriagli Nabih F","year":"2011","unstructured":"Oueriagli Nabih F, Touhami M, Laffinti A, Abilkacem L. Mood disorder after malaria prophylaxis with mefloquine (two case reports). Encephale. 2011, 37:393-6. 10.1016\/j.encep.2011.01.013","journal-title":"Encephale"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/350417","article-title":"Severe neuropsychiatric reaction in a deployed military member after prophylactic mefloquine","volume":"2011","author":"Peterson AL","year":"2011","unstructured":"Peterson AL, Seegmiller RA, Schindler LS. Severe neuropsychiatric reaction in a deployed military member after prophylactic mefloquine. Case Rep Psychiatry. 2011, 2011:350417. 10.1155\/2011\/350417","journal-title":"Case Rep Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e318167a9e2","article-title":"Psychotic mania associated with mefloquine in a bipolar patient","volume":"101","author":"Brumbaugh M","year":"2008","unstructured":"Brumbaugh M, Price P, Fagan N, Hsieh H. Psychotic mania associated with mefloquine in a bipolar patient. South Med J. 2008, 101:550-1. 10.1097\/SMJ.0b013e318167a9e2","journal-title":"South Med J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.13.2.302","article-title":"Cognitive and neuropsychiatric side effects of mefloquine","volume":"13","author":"Javorsky DJ","year":"2001","unstructured":"Javorsky DJ, Tremont G, Keitner GI, Parmentier AH. Cognitive and neuropsychiatric side effects of mefloquine. J Neuropsychiatry Clin Neurosci. 2001, 13:302. 10.1176\/jnp.13.2.302","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2014.08.001","article-title":"Depersonalization\/derealization disorder after exposure to mefloquine","volume":"56","author":"McEvoy K","year":"2015","unstructured":"McEvoy K, Anton B, Chisolm MS. Depersonalization\/derealization disorder after exposure to mefloquine. Psychosomatics. 2015, 56:98-102. 10.1016\/j.psym.2014.08.001","journal-title":"Psychosomatics"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0890-8567(09)66572-2","article-title":"Case study: neuropsychiatric symptoms associated with the antimalarial agent mefloquine","volume":"36","author":"Clattenburg RN","year":"1997","unstructured":"Clattenburg RN, Donnelly CL. Case study: neuropsychiatric symptoms associated with the antimalarial agent mefloquine. J Am Acad Child Adolesc Psychiatry. 1997, 36:1606-8. 10.1016\/S0890-8567(09)66572-2","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref20","article-title":"Mefloquine-induced mania in a 22-year-old Chinese man","volume":"47","author":"Tor PC","year":"2006","unstructured":"Tor PC, Lee HY, Tan CH. Mefloquine-induced mania in a 22-year-old Chinese man. Singapore Med J. 2006, 47:549-50.","journal-title":"Singapore Med J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181de80f8","article-title":"Mania associated with mefloquine prophylaxis","volume":"30","author":"Yelmo S","year":"2010","unstructured":"Yelmo S, Morera-Fumero AL, Henry M, Renshaw A, Gracia-Marco R. Mania associated with mefloquine prophylaxis. J Clin Psychopharmacol. 2010, 30:339-41. 10.1097\/JCP.0b013e3181de80f8","journal-title":"J Clin Psychopharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199407073310120","article-title":"Central anticholinergic syndrome with the antimalarial drug mefloquine","volume":"331","author":"Speich R","year":"1994","unstructured":"Speich R, Haller A. Central anticholinergic syndrome with the antimalarial drug mefloquine. N Engl J Med. 1994, 331:57-8. 10.1056\/NEJM199407073310120","journal-title":"N Engl J Med"},{"key":"ref23","article-title":"Bipolar disorder after mefloquine treatment","volume":"26","author":"Even C","year":"2001","unstructured":"Even C, Friedman S, Lanouar K. Bipolar disorder after mefloquine treatment. J Psychiatry Neurosci. 2001, 26:252-3.","journal-title":"J Psychiatry Neurosci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.127113","article-title":"Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events","volume":"72","author":"van Riemsdijk MM","year":"2002","unstructured":"van Riemsdijk MM, Sturkenboom MC, Ditters JM, Ligthelm RJ, Overbosch D, Stricker BH. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther. 2002, 72:294-301. 10.1067\/mcp.2002.127113","journal-title":"Clin Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02035.x","article-title":"Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine","volume":"57","author":"van Riemsdijk MM","year":"2004","unstructured":"van Riemsdijk MM, Sturkenboom MC, Ditters JM, Tulen JH, Ligthelm RJ, Overbosch D, Stricker BH. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol. 2004, 57:506-12. 10.1046\/j.1365-2125.2003.02035.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7071.1552b","article-title":"Adverse events associated with mefloquine. Study in returned travellers confirms authors' findings","volume":"313","author":"Corbett EL","year":"1996","unstructured":"Corbett EL, Doherty JP, Behrens RH. Adverse events associated with mefloquine. Study in returned travellers confirms authors' findings. BMJ. 1996, 313:1552. 10.1136\/bmj.313.7071.1552b","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7056.525","article-title":"Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers","volume":"313","author":"Barrett PJ","year":"1996","unstructured":"Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ. 1996, 313:525-8. 10.1136\/bmj.313.7056.525","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1086\/322694","article-title":"Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study","volume":"33","author":"Overbosch D","year":"2001","unstructured":"Overbosch D, Schilthuis H, Bienzle U, et al.. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis. 2001, 33:1015-21. 10.1086\/322694","journal-title":"Clin Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2014.10.021","article-title":"Acute and long-term psychiatric side effects of mefloquine: a follow-up on Danish adverse event reports","volume":"13","author":"Ringqvist \u00c5","year":"2015","unstructured":"Ringqvist \u00c5, Bech P, Glenth\u00f8j B, Petersen E. Acute and long-term psychiatric side effects of mefloquine: a follow-up on Danish adverse event reports. Travel Med Infect Dis. 2015, 13:80-8. 10.1016\/j.tmaid.2014.10.021","journal-title":"Travel Med Infect Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(93)90037-q","article-title":"Neuropsychiatric side effects of mefloquine in Africans","volume":"87","author":"Sowunmi A","year":"1993","unstructured":"Sowunmi A, Salako LA, Oduola AM, Walker O, Akindele JA, Ogundahunsi OA. Neuropsychiatric side effects of mefloquine in Africans. Trans R Soc Trop Med Hyg. 1993, 87:462-3. 10.1016\/0035-9203(93)90037-q","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7423.1078","article-title":"Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study","volume":"327","author":"Schlagenhauf P","year":"2003","unstructured":"Schlagenhauf P, Tschopp A, Johnson R, et al.. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ. 2003, 327:1078. 10.1136\/bmj.327.7423.1078","journal-title":"BMJ"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2014.03.002","article-title":"Idiosyncratic quinoline central nervous system toxicity: historical insights into the chronic neurological sequelae of mefloquine","volume":"4","author":"Nevin RL","year":"2014","unstructured":"Nevin RL. Idiosyncratic quinoline central nervous system toxicity: historical insights into the chronic neurological sequelae of mefloquine. Int J Parasitol Drugs Drug Resist. 2014, 4:118-25. 10.1016\/j.ijpddr.2014.03.002","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198510030-00001","article-title":"Clinical pharmacokinetics of antimalarial drugs","volume":"10","author":"White NJ","year":"1985","unstructured":"White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet. 1985, 10:187-215. 10.2165\/00003088-198510030-00001","journal-title":"Clin Pharmacokinet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/528825-systematic-review-of-neuropsychiatric-side-effects-induced-by-mefloquine-evidence-from-case-reports-and-clinical-studies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:54:35Z","timestamp":1787669675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/528825-systematic-review-of-neuropsychiatric-side-effects-induced-by-mefloquine-evidence-from-case-reports-and-clinical-studies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.115158","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}